MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

ICMR Creates Vaccine for Shigella, Licenses to Hilleman Laboratories

ICMR Creates Vaccine for Shigella, Licenses to Hilleman Laboratories

The first ever vaccine for Shigella, an intestinal disease has been licensed by the Indian Council of Medical Research (ICMR) on April 23 this year. The license agreement was carried out by India Limited (BCIL), a Biotech Consortium with NICED on behalf of Hilleman laboratories and ICMR.

The licensed vaccine was given to MSD Wellcome Trust Hilleman Laboratories Pvt Ltd for further scaling up and commercialisation.

The new breakthrough was carried out ICMR-National Institute of Cholera and Enteric Diseases (NICED). The new vaccine for Shigella was created in the form of heat-treated/formalin killed vaccines. Apart from that, another next-gen vaccine such as OmpA nano-formulation and OMVs (Outer Membrane Vesicles) is also being created to control the spread the Shigella infection.

The bodies involved in the creation of the licensed vaccine candidate are ICMR, Japan’s Okayama University and National Institute of Infectious Diseases. The translation of the licensed vaccine candidate will go through a stringent pre-clinical and clinical development before hitting the market for use.

The Shigella vaccine which has high potential should help the children hailing from low and mid-income families.

The new development is the first ever vaccine produced to treat Shigella. Currently, the world wide treatment for the disease is being treated through antibiotics; therefore, the major concern on antibiotic resistance and global emergence makes the new vaccine the only solution for the disease.

The new development is a big achievement for ICMR.

YOU MAY ALSO LIKE

Marketing Partnership: NBA, McDonald’s Will Jointly open NBA Experience Zones India

There is good news for all basketball fans in India. Very soon, NBA themed promotions and experience zones will be launched in India. The announcement...

Dunzo to Raise Funds from Google, others

Dunzo, the app which is trying to make life easier for the people upto some extent plans to raise about Rs. 183 crore from different investors which a...

Sapta Shakti Command Will Be Displaying Defence Technology Equipment at Jaipur Military Station

This event is organised with an aim to provide an opportunity where one and all can experience the developments in the field of defence and security-r...

Samsung is All Set to Roll out Its Galaxy A9 Smartphone On November 20

After Samsung unveiled its new Galaxy A9 smartphone in Singapore last month, the company is all set to launch it in India on November 20. In Singapore...

RECOMMENDED